AbbVie to acquire Apogee Therapeutics for $10.9 billion in cash

AbbVie announced a definitive agreement to acquire Apogee Therapeutics for $135.11 per share, totaling approximately $10.9 billion in equity value. The acquisition adds a clinical-stage immunology pipeline focused on inflammatory and immunological diseases including atopic dermatitis and asthma, strengthening AbbVie's market position in immunology.